Key facts
- Tubulis’s last known valuation is $5.8B (Apr 2026).
- It has raised $618.5M across 1 recorded rounds; the latest was Later Stage VC (Series C) ($360.7M) in Oct 2025.
- Notable investors include Fidelity Management & Research Company, High-Tech Gründerfonds, Blackstone, Bayern Kapital, Venrock — 26 tracked in total.
- Status: Privately Held (backing).
Leadership
- Andreas MontagVice President
- Björn HockChief Development Officer
- Charles FuchsChief Medical Officer
- Halley GilbertChief Legal Officer & Chief Operating Officer
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for Tubulis
Funding rounds
1 roundsAbout Tubulis
Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases. The company's chemotherapeutic drugs are uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology, enabling doctors to treat cancer patients without any side effects related to chemotherapy.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Planegg-Martinsried, Germany
- Founded
- 2012
- Employees
- 107
- Website
- tubulis.com/
- Ownership
- Privately Held (backing)
Tubulis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tubulis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tubulis in its N-PORT filings yet. We sweep new filings monthly.